TRACON Pharmaceuticals Inc TCON:NASDAQ

Last Price$1.98NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/28/22

Today's Change+0.08(4.21%)
Bid (Size)$1.77 (1)
Ask (Size)$2.10 (2)
Day Low / High$1.90 - 2.10
Volume158.7 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/28/2022

 

TRACON Pharmaceuticals Inc ( NASDAQ )

Price: $1.98
Change: +0.08 (4.21%)
Volume: 158.7 K
4:00PM ET 6/28/2022
 
 

Ocuphire Pharma Inc ( NASDAQ )

Price: $1.96
Change: -0.05 (2.49%)
Volume: 25.4 K
4:00PM ET 6/28/2022
 
 

Alimera Sciences Inc ( NASDAQ )

Price: $5.54
Change: -0.10 (1.77%)
Volume: 2.3 K
3:59PM ET 6/28/2022
 
 

Astria Therapeutics Inc ( NASDAQ )

Price: $3.05
Change: +0.04 (1.33%)
Volume: 29.1 K
4:00PM ET 6/28/2022
 
 

Aileron Therapeutics Inc ( NASDAQ )

Price: $0.41
Change: -0.008 (1.95%)
Volume: 139.0 K
4:00PM ET 6/28/2022
 

Read more news Recent News

TRACON Pharmaceuticals' Amended Cancer Treatment Trial Protocol Receives Approval From 30 Sites in US, UK
10:52AM ET 4/19/2022 MT Newswires

TRACON Pharmaceuticals (TCON) said Tuesday its amended cancer treatment trial protocol has now been approved by institutional review boards or ethics...

Wall Street Set for Gains Ahead of Fed's Rate Decision
9:24AM ET 3/16/2022 MT Newswires

US stocks were set for an upbeat open Wednesday as traders digested economic data and looked ahead to the Federal Reserve's interest rate decision. Dow...

TRACON Pharmaceuticals Q4 Loss Widens
5:20PM ET 3/15/2022 MT Newswires

TRACON Pharmaceuticals (TCON) said Tuesday its net loss widened to $0.40 per share in Q4 from $0.31 per share a year earlier. Analysts polled by Capital...

Tracon Pharma Says Dosing Cancer Patients Following FDA Nod for New Envafolimab Protocol; Shares Gain
10:20AM ET 3/10/2022 MT Newswires

Tracon Pharmaceuticals (TCON) said Thursday patient dosing is underway after the US Food and Drug Administration approved a higher dosage of its cancer...

Company Profile

Business DescriptionTRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA. View company web site for more details
Address4350 La Jolla Village Drive
San Diego, California 92122-1243
Phone+1.858.550.0780
Number of Employees26
Recent SEC Filing06/27/20224
President, Chief Executive Officer & DirectorCharles P. Theuer
Chief Financial OfficerScott B. Brown
Executive Vice President-Clinical OperationsBonne J. Adams
Chief Medical OfficerJames L. Freddo

Company Highlights

Price Open$1.95
Previous Close$1.98
52 Week Range$1.24 - 7.23
Market Capitalization$40.1 M
Shares Outstanding20.3 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.83
Beta vs. S&P 500N/A
Revenue$3.0 M
Net Profit Margin-9,559.54%
Return on Equity-292.18%

Analyst Ratings as of 06/15/2022

Buy
4
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset